Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 25

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 25
---
,742,607 |

<div align='center'>19</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

Nine-month period ended December 31, 2024 (From April 1 to December 31, 2024)

|                                            |     |                                              |     | JPY (millions) |           |     |         |     |                                                                                                     |           |     |          |     |         |     |          |     |           |     |                            |     |           |     |         |
|                                            |     | Equity attributable to owners of the Company |     |                |           |     |         |     |                                                                                                     |           |     |          |     |         |     |          |     |           |     |                            |     |           |     |         |
|                                            |     | Share                                        
 capital                                      |     |                |           |     | Share   
 premium |     |                                                                                                     |           |     | Treasury 
 shares   |     |         |     | Retained 
 earnings |     |           |     | Other components of equity |     |           |     |         |
|                                            |     |                                              |     | Exchange       
 differences    
 on translation 
 of foreign     
 operations     |           |     |         |     | Changes in fair value of financial assets measured at fair value through other comprehensive income |           |     |          |     |         |     |          |     |           |     |                            |     |           |     |         |
| As of April 1, 2024                        |     |                                              |     |                | 1,676,596 |     |         |     |                                                                                                     | 1,747,414 |     |          |     | -51,259 |     |          |     | 1,391,203 |     |                            |     | 2,573,407 |     |  15,729 |
| Net profit for the period                  |     |                                              |     |                |           |     |         |     |                                                                                                     |           |     |          |     |         |     |          |     |   211,083 |     |                            |     |           |     |         |
| Other comprehensive income (loss)          |     |                                              |     |                |           |     |         |     |